ArticleBMC infectious diseases2013
Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan.
Article in BMC infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Role of Serum Inflammatory Biomarkers in Risk Stratification of Hospitalized Children with Macrolide-Non-ResponsiveChildren (Basel, Switzerland) · 2026Article
- Pulmonary thromboembolism due to Mycoplasma pneumoniae in children: a case report and literature review.BMC pediatrics · 2024Review
- [Efficacy of prolonged azithromycin versus switching to doxycycline in the treatment of macrolide-unresponsiveZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Article
- Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.World journal of pediatrics : WJP · 2024Review
- Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia.European journal of pediatrics · 2024Review
- Structure-Based Virtual Screening, ADMET Properties Prediction and Molecular Dynamics Studies Reveal Potential Inhibitors ofLife (Basel, Switzerland) · 2024Article
- Characteristics of theAntibiotics (Basel, Switzerland) · 2023Article
- Proteomic and Phenotypic Studies of Mycoplasma pneumoniae Revealed Macrolide-Resistant Mutation (A2063G) Associated Changes in Protein Composition and Pathogenicity of Type I Strains.Microbiology spectrum · 2023Article
- Macrolide versus Non-Macrolide in Combination with Steroids for the Treatment of Lobar or SegmentalAntibiotics (Basel, Switzerland) · 2022Article
- RefractoryJournal of clinical medicine · 2022Review
- Clinical Characteristics of Macrolide-RefractoryJournal of clinical medicine · 2022Article
- The Role of Respiratory Flora in the Pathogenesis of Chronic Respiratory Diseases.BioMed research international · 2021Review
- Macrolide resistance and molecular typing of Mycoplasma pneumoniae infections during a 4 year period in Spain.The Journal of antimicrobial chemotherapy · 2020Article
- Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children.Korean journal of pediatrics · 2019Article
- Antimicrobial susceptibility and genotyping ofAntimicrobial resistance and infection control · 2019Article
- Review
- Mycoplasma pneumoniae from the Respiratory Tract and Beyond.Clinical microbiology reviews · 2017Review
- In vitro antibacterial activity of α-methoxyimino acylide derivatives against macrolide-resistant pathogens and mutation analysis in 23S rRNA.The Journal of antibiotics · 2017Article
- Encouraging rational antibiotic use in childhood pneumonia: a focus on Vietnam and the Western Pacific Region.Pneumonia (Nathan Qld.) · 2017Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent epidemiologic data suggest that the prevalence of macrolide resistant Mycoplasma pneumoniae (MR-M. pneumoniae) is increasing rapidly worldwide. This study assessed the present status of M. pneumoniae infection in Japan and clinical end-points to distinguish children with MR-M. pneumoniae.
methodsDuring an outbreak of M. pneumoniae infections in Fukuoka, Japan in 2010-11, a total of 105 children with clinically suspected M. pneumoniae infection were enrolled. M. pneumoniae was analyzed for macrolide resistance in domain V of the 23S rRNA gene. Sixty -five patients with PCR positive for M. pneumoniae were analyzed with regard to clinical symptoms, efficacy of several antimicrobial agents and several laboratory data.
resultsCausative pathogens were detected in 81.0% (85 of 105) and M. pneumoniae was identified 61.9% (65 of 105). The resistance rate of M. pneumoniae was 89.2% (58 of 65) in this general pediatric outpatient setting. Patients infected with MR-M. pneumoniae showed longer times to resolution of fever and required frequent changes of the initially prescribed macrolide to another antimicrobial agent. We observed three different genotypes of M. pneumoniae including the rarely reported A2063T mutation (A2063G: 31 strains, A2063T: 27 strains, no mutation: 7 strains). Drug susceptibility testing showed different antimicrobial susceptibility profiles for each genotype. Serum IFN-gamma, IL-6 and IP-10 levels were higher in patients with MR-genotypes than in those infected with no-mutation strains (p < 0.001).
conclusionsMacrolide resistance is more common than previously thought and a small epidemic of rarely reported A2063T mutation was observed in Fukuoka, Japan. Furthermore our results reveal the possibility that levels of certain inflammatory cytokines may be a candidate to predict MR-M.pneumoniae infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.